Home/Pipeline/BioVascular Pancreas™

BioVascular Pancreas™

Type 1 Diabetes

PreclinicalNot Specified

Key Facts

Indication

Type 1 Diabetes

Phase

Preclinical

Status

Not Specified

Company

Humacyte

About Humacyte

Humacyte is transforming regenerative medicine with its proprietary platform for developing acellular, bioengineered human tissues designed to be universally implantable without immune rejection. The company achieved a landmark FDA approval in December 2024 for Symvess™ for vascular trauma and is advancing a broad pipeline targeting vascular access, coronary artery disease, and complex organ replacement. Led by founder and renowned physician-scientist Dr. Laura Niklason, Humacyte aims to address a wide range of injuries and chronic conditions with its off-the-shelf, regenerative tissue products.

View full company profile

Therapeutic Areas

Vascular Surgery Nephrology Cardiology Endocrinology Pulmonology Urology Otolaryngology Gastroenterology Trauma

Other Type 1 Diabetes Drugs

Drug	Company	Phase	Status
VX-880	Vertex Pharmaceuticals	Phase 1/2	Active
VCTX210 (Vertex collab.)	CRISPR Therapeutics	Phase 1/2	Clinical
UP421	Sana Biotechnology	Pre-Clinical	Active
SC451	Sana Biotechnology	Pre-Clinical	Active
ORMD-0801	Oramed Pharmaceuticals	Phase 2	Completed
Undisclosed Novel Strategy	CG Scientific	Pre-clinical	Early Research